About CARBOGEN AMCIS
CARBOGEN AMCIS is a company based in Bubendorf (Switzerland) founded in 1990 was acquired by Dishman Group in August 2006. CARBOGEN AMCIS has raised $4.36 million across 2 funding rounds from investors including HHS, Dishman Group and Solutia. CARBOGEN AMCIS offers products and services including API Manufacturing, Drug Product Development, and Specialities Manufacturing. CARBOGEN AMCIS operates in a competitive market with competitors including Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others.
- Headquarter Bubendorf, Switzerland
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website carbogen-amcis.com
- Social LinkedIn X YouTube
- Acquired by Dishman Group (Aug 2006)
- Total Equity Funding$4.36M (USD)
in 2 rounds
- Latest Funding Round$4.36M (USD), Series A
Sep 2021
- InvestorsHHS
& 2 more
- Acquired by
Products & Services of CARBOGEN AMCIS
CARBOGEN AMCIS offers a comprehensive portfolio of products and services, including API Manufacturing, Drug Product Development, and Specialities Manufacturing.
Develops and manufactures active pharmaceutical ingredients for clinical use.
Offers formulation and analytical services for sterile drug products.
Produces Vitamin D analogs and cholesterol derivatives under GMP standards.
Apps and channels of CARBOGEN AMCIS
its YouTube channel CARBOGEN AMCIS AG has 124 subscribers and 21 videos.
Videos from CARBOGEN AMCIS
The most watched videos on CARBOGEN AMCIS's YouTube channel, CARBOGEN AMCIS AG (124 subscribers). Click a video to play it here.
More on CARBOGEN AMCIS AG.
Funding Insights of CARBOGEN AMCIS
CARBOGEN AMCIS has successfully raised a total of $4.36M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.36 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.36M
- Total Rounds 2
- Last Round Series A — $4.36M
- First Round $105,770
(Sep 2009)
- Investors Count 1
All 2 funding rounds of CARBOGEN AMCIS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $4.36M | Series A | – | – | – |
| Sep 2009 | $105,770 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in CARBOGEN AMCIS
CARBOGEN AMCIS has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Dishman Group and Solutia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Additives, functional products, specialty chemicals, and fibers are provided. | 1997 | solutia.com | United States | |
CDMO offering its services for the development of APIs and intermediates | 1983 | dishmangroup.com | Ahmedabad, India |
Investor details for CARBOGEN AMCIS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CARBOGEN AMCIS
181 people are tracked at CARBOGEN AMCIS (37 in leadership, 4 in board & advisors, 140 in team).
| Name | Role | Group |
|---|---|---|
Fabian Hasnik | Manager And Deputy Head Of Quality Assurance | Leadership |
Stephan Fritschi | EVP, Business Units & Deputy CEO | Leadership |
Robert Rhodes | Director Operations | Leadership |
Jessica Huang | Head Of M&a; Site SAP Project Lead | Leadership |
Dieter Thüer | VP, Human Resources | Leadership |
François Baduel | VP, Sales & Marketing | Leadership |
Charlotte Lefébure | HR Director Head Of HR | Leadership |
Roland Keilitz | Head Of Pr&d | Leadership |
Mathias Brodmann | Head Of SAP Technical | Leadership |
Frank Hamhuis | Director Operations BU Specialities | Leadership |
Sara Simbolon | HR Director | Leadership |
Anton Gayring | Director PMO / BU Drug Substance | Leadership |
Dirk Badura | Global Head Digital Quality Solutions | Leadership |
Marc Lanz | Head Of Innovation | Leadership |
Michael Theis | Sr. Manager Qc&a (acting Head Of) | Leadership |
Jan Vossen | Head Of QA & Fachtechnisch Verantwortliche Person | Leadership |
Michael Roeder | Head Of Project Management Drug Substance | Leadership |
Lucie Framinet | Head Of Marketing | Leadership |
Thomas Schlatterer | Commercial Director Drug Substance | Leadership |
Patricia Nünlist | HR Business Partner | Leadership |
161 more people are available in the full profile.
Complete people profiles for CARBOGEN AMCIS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CARBOGEN AMCIS
5 dated milestones of CARBOGEN AMCIS across 31 years, from founding to its latest funding, stage changes and deals.
- Founded CARBOGEN AMCIS is founded.
- Exit Acquired by Solutia.
- Exit Acquired by Dishman Group.
- Funding First funding round of $106K.
- Funding Latest funding round, Series A, of $4.4M.
Competitors of CARBOGEN AMCIS
CARBOGEN AMCIS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| unither-pharma.com | 1993 | Paris, France | – | – | Contract development and manufacturing organization for proprietary and generic drugs | |
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| recipharm.com | 1995 | Jordbro, Sweden | – | 1,083 | Pharmaceutical development and manufacturing services are offered contractually. | |
| jubl.com | 1978 | Noida, India | – | – | Company offering a suite of R&D and manufacturing services for small molecules and generics | |
| corerxpharma.com | 2006 | Clearwater, United States | $15M | – | CDMO with a focus on early phase drug product development | |
| windlas.com | 2001 | Gurugram, India | $12.96M | 1,264 | Biopharma regulatory affairs, quality control, and strategy services are provided. | |
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. | |
| kezzler.com | 2001 | Oslo, Norway | $6.73M | – | Mass serialization solutions for a wide range of industries |
Detailed competitors of CARBOGEN AMCIS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CARBOGEN AMCIS
The website of CARBOGEN AMCIS (carbogen-amcis.com) receives about 5.5K visits a month and ranks #2,631,505 among all websites worldwide, #3,592 in Biotechnology and Pharmaceuticals.
- Monthly visits5.5K
▼ 33.5% vs previous month
- Unique visitors3.3K
per month
- Global rank#2,631,505
among all websites
- Category rank#3,592
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.8
- Average visit1 min 34 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with CARBOGEN AMCIS. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kemwellbiopharma.com | 100% | 6.2K | #2,788,016 | View details | |
| dptlabs.com | 94% | 1.5K | #8,022,749 | View details | |
| wuxiapptec.com | 93% | 107.6K | #296,852 | View details | |
| irisys.com | 93% | – | – | View details | |
pharmaceuticalmanufacturer.media | pharmaceuticalmanufacturer.media | 88% | – | #1,499,999 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for CARBOGEN AMCIS
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Carbogen Amcis
Complete news archive for CARBOGEN AMCIS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CARBOGEN AMCIS
10 companies that operate in the same segment as CARBOGEN AMCIS (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CARBOGEN AMCIS
CARBOGEN AMCIS was founded in 1990 and raised its 1st funding round 19 years after it was founded.
CARBOGEN AMCIS is headquartered in Bubendorf, Switzerland. It is registered at Bubendorf, Basel-landschaft, Switzerland.
CARBOGEN AMCIS is a funded company, having raised a total of $4.36M across 2 funding rounds to date. The company's 1st funding round was a Grant of $105.77K, raised on Sep 2009.
Founded in 1990 and based in Bubendorf, Switzerland, CARBOGEN AMCIS operates as a contract development and manufacturing organization in the pharmaceutical sector. Services encompass chemical process research, API production for preclinical, clinical, and commercial stages, and analytical support including chromatography and parenteral formulations. The company was acquired by Dishman Pharma in 2006 and functions as its subsidiary, focusing on high-potency compounds.
CARBOGEN AMCIS's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
CARBOGEN AMCIS offers API Manufacturing, Drug Product Development, and Specialities Manufacturing.
CARBOGEN AMCIS has 3 investors. Key investors include HHS, Dishman Group, and Solutia.
Yes. CARBOGEN AMCIS was acquired by Dishman Group in August 2006.